RxDoctor Payments Data

Ricardo Ramirez, MD

Ophthalmology · Orlando, FLNPI 1932192341

Payments from drug & device makers

$3,807in general payments, 2019–2025

Across 243 payments — averaging $15.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Bausch & Lomb, A Division Of Bausch Health US, LLC$569
  • Kala Pharmaceuticals, Inc.$415
  • Bausch & Lomb Americas Inc.$367
  • Alcon$271
  • Sun Pharmaceutical Industries Inc.$175
  • plus $744 from 10 others

What the payments were for

  • Food & beverage$3,807100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,807 in reported general payments places this provider in the 60th percentile of 1,405 ophthalmology providers in Florida.

See all ophthalmology providers in Florida

Medicare billing

Part B allowed, 2024
$210,284
Medicare patients
1,121
Services billed
2,179

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LumiganBimatoprost144$79,380
RestasisCyclosporine28$35,644
VyzultaLatanoprostene Bunod43$22,409
RocklatanNetarsudil Mesylat/Latanoprost31$14,392
SimbrinzaBrinzolamide/Brimonidine Tart44$14,260
CombiganBrimonidine Tartrate/Timolol37$12,759
Alphagan PBrimonidine Tartrate24$8,789
RhopressaNetarsudil Mesylate19$8,756
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol28$7,154
Latanoprost425$6,290
Brimonidine Tartrate70$4,486
Brinzolamide19$3,163
Travoprost19$3,085
Dorzolamide Hcl98$1,775
Prednisolone Acetate36$1,426

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLumigan, Restasis, Combigan, Alphagan P$1,265$136,572233 claims
Aerie Pharmaceuticals, Inc.Rocklatan, Rhopressa$139$23,14750 claims
Bausch & Lomb Americas Inc.Vyzulta$367$22,40943 claims
AlconSimbrinza$271$14,26044 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 1,405 ophthalmology providers in Florida.

Other ophthalmology in Orlando

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →